Description: Generation Bio is an innovative genetic medicines company focused on creating a new class of gene therapy to provide durable, redosable treatments for patients suffering from both rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company is designing therapies to provide targeted delivery of genetic payloads that include large and multiple genes across a broad array of tissues, and to be redosable for individualized and extended treatment throughout a patient’s life. The platform is designed to expand access to treatments for rare diseases and to address prevalent diseases through efficient, scalable manufacturing.
Home Page: generationbio.com
GBIO Technical Analysis
301 Binney Street
Cambridge,
MA
02142
United States
Phone:
617 655 7500
Officers
| Name | Title |
|---|---|
| Dr. Cameron Geoffrey McDonough M.D. | Pres, CEO, Sec. & Director |
| Dr. Matthew Norkunas M.B.A., M.D. | Chief Financial Officer |
| Dr. Matthew Stanton Ph.D. | Chief Scientific Officer |
| Dr. Douglas Kerr M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Dr. Tracy Zimmermann Ph.D. | Chief Devel. Officer |
| Dr. Mark D. Angelino Ph.D. | Co-Founder |
| Dr. Robert Kotin Ph.D. | Co-Founder & Advisor |
| Ms. Antionette Paone M.B.A., M.S. | Chief Operating Officer |
| Dr. Jennifer Elliott Esq., J.D., Ph.D. | Chief Legal Officer |
| Dr. Phillip Samayoa Ph.D. | Chief Strategy Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9277 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-06-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 150 |